君实生物(01877.HK)：JS212临床试验申请获得FDA批准

Core Viewpoint - Junshi Biosciences (01877.HK) has received approval from the U.S. Food and Drug Administration (FDA) for its clinical trial application of the EGFR/HER3 bispecific antibody-drug conjugate (code: JS212) for the treatment of advanced solid tumors [1] Group 1 - The FDA notification indicates a significant milestone for Junshi Biosciences in advancing its oncology pipeline [1] - The approval allows the company to initiate clinical trials, which could lead to potential market opportunities in the oncology sector [1] - JS212 represents a novel therapeutic approach targeting specific cancer pathways, highlighting the company's commitment to innovation in cancer treatment [1]